目的 探讨甲状腺乳头状癌(PTC)患者BRAF V600E基因突变率及其与临床病理特征的关系.方法 收集2014年8月至2015年10月山西省肿瘤医院临床及病理资料完整的PTC患者265例,包括经典型226例,滤泡型29例,高细胞型3例,弥漫硬化型2例,嗜酸细胞型2例,囊性型3例.全部经实时荧光定量聚合酶链反应(RT-PCR)检测BRAF V600E基因突变.采用Pearsonχ2检验和Fisher确切概率法分析PTC患者基因突变与临床病理特征间的关系.结果 PTC患者的BRAF V600E基因突变率为73.21 %(194/265).不同年龄、性别、肿瘤部位、肿瘤个数、被膜外侵犯患者的BRAF V600E基因突变率比较,差异均无统计学意义(均P>0.05),而不同肿瘤最大径、病理组织学亚型、淋巴结转移、临床分期患者的BRAF V600E基因突变率比较,差异均有统计学意义(均P<0.05).结论 BRAF V600E基因突变阳性的PTC患者具有较差的临床病理学特征,BRAF V600E基因突变可能成为预测进展型PTC患者的一项指标.%Objective To discuss the BRAF V600E mutation rate in papillary thyroid carcinoma (PTC) and its relationship with the clinicopathological features. Methods Two hundred and sixty-five PTC patients(including 226 cases of classical type,29 cases of follicular type, 3 cases of high cell type, 2 cases of diffuse sclerosis type, 2 cases of eosinophilic type, 3 cases of cystic type) from August 2014 to October in Shanxi Provincial Cancer Hospital, were collected with completely clinical and pathological information. The BRAF V600E mutation was detected by real-time polymerase chain reaction (RT-PCR) method. Pearson χ 2 test and the exact probability method were used to analysis the relationship between gene mutations and clinicopathological data. Results BRAF V600E mutation rate in PTC patients was 73.21 %(194/265). There was no significant difference in the mutation rate of BRAF V600E among patients with different age, gender, tumor location,tumor number and extravaginal invasion(all P>0.05),but the mutation rates of BRAF V600E gene in patients with different tumor size, histopathological subtypes, lymph node metastasis and clinical stage were significantly different(all P<0.05).Conclusion The PTC patients with positive BRAF V600E mutation have poor clinicopathological features,and BRAF V600E mutation may be a predictor of advanced PTC.
展开▼
